KCNK3: new gene target for pulmonary hypertension?

References

• Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954;30(3):195-207
   PubMedGoogle Scholar
• Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 2013;34(5):568-80
   PubMed Web of Science ®Google Scholar
• Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S32-42
   Google Scholar
• Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369(4):351-61
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26(1):81-4
   PubMed Web of Science ®Google Scholar
• Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3):737-44
   PubMed Web of Science ®Google Scholar
• Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186(9):892-6
   PubMed Web of Science ®Google Scholar
• Girerd B, Montani D, Eyries M, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010;11:73
   PubMed Web of Science ®Google Scholar
• Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59(5):446-8
   PubMed Web of Science ®Google Scholar
• Shintani M, Yagi H, Nakayama T, et al. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009;46(5):331-7
   PubMed Web of Science ®Google Scholar
• Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011;32(12):1385-9
   PubMed Web of Science ®Google Scholar
• Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012;5(3):336-43
   PubMedGoogle Scholar
• Bittner S, Meuth SG. Targeting ion channels for the treatment of autoimmune neuroinflammation. Ther Adv Neurol Disord 2013;6(5):322-36
   PubMed Web of Science ®Google Scholar
• Tang Y, Stahl-Herz J, Sampson BA. Molecular diagnostics of cardiovascular diseases in sudden unexplained death. Cardiovasc Pathol 2014;23(1):1-4
   PubMed Web of Science ®Google Scholar
• Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45(15):1132-44
   PubMed Web of Science ®Google Scholar
• Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol 2000;279(5):F793-801
   Web of Science ®Google Scholar
• Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006;98(8):1072-80
   PubMed Web of Science ®Google Scholar
• Hartness ME, Lewis A, Searle GJ, et al. Combined antisense and pharmacological approaches implicate hTASK as an airway O(2) sensing K(+) channel. J Biol Chem 2001;276(28):26499-508
   PubMed Web of Science ®Google Scholar
• Osipenko ON, Evans AM, Gurney AM. Regulation of the resting potential of rabbit pulmonary artery myocytes by a low threshold, O2-sensing potassium current. Br J Pharmacol 1997;120(8):1461-70
   PubMed Web of Science ®Google Scholar
• Tang B, Li Y, Nagaraj C, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009;41(4):476-83
   PubMed Web of Science ®Google Scholar
• Seyler C, Duthil-Straub E, Zitron E, et al. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br J Pharmacol 2012;165(5):1467-75
   PubMed Web of Science ®Google Scholar
• Trapp S, Aller MI, Wisden W, Gourine AV. A role for TASK-1 (KCNK3) channels in the chemosensory control of breathing. J Neurosci 2008;28(35):8844-50
   PubMed Web of Science ®Google Scholar
• Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 2012;39(2):329-43
   PubMed Web of Science ®Google Scholar
• Machado RD. Seeking the right targets: gene therapy advances in pulmonary arterial hypertension. Eur Respir J 2012;39(2):235-7
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372(9640):719-27
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12-18
   PubMed Web of Science ®Google Scholar
• Noel S, Dhooghe B, Leal T. PDE5 inhibitors as potential tools in the treatment of cystic fibrosis. Front Pharmacol 2012;3:167
   PubMed Web of Science ®Google Scholar
• Frump AL, Lowery JW, Hamid R, et al. Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension. PLoS One 2013;8(11):e80319
   Web of Science ®Google Scholar
• Drake KM, Dunmore BJ, McNelly LN, et al. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013;49(3):403-9
   PubMed Web of Science ®Google Scholar
• Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar